<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph E Marine, MD, FACC, FHRS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea M Russo, MD, FACC, FHRS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Lévy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H362963031"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Life-threatening ventricular arrhythmias, including sustained ventricular tachycardia (VT) and ventricular fibrillation (VF), are common in patients with systolic heart failure (HF) and dilated cardiomyopathy and may lead to sudden cardiac death (SCD). Primary prevention of SCD refers to medical or interventional therapy undertaken to prevent SCD in patients who have not experienced symptomatic life-threatening sustained VT/VF or sudden cardiac arrest (SCA) but who are felt to be at an increased risk for such an event. The primary prevention of SCD in patients with HF and cardiomyopathy with reduced ejection fraction, either due to coronary heart disease or a dilated nonischemic etiology, will be reviewed here with emphasis on the role of implantable cardioverter-defibrillators (ICDs). The different types of ventricular arrhythmias, the effects of HF therapy on ventricular arrhythmias, the role of electrophysiologic testing, and the secondary prevention of SCD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p>The approaches to the treatment of ventricular arrhythmias related to specific heart muscle diseases or primary electrical system diseases such as hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, isolated left ventricular noncompaction, Chagas disease, Brugada syndrome, long QT syndrome, and other channelopathies are discussed elsewhere. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk", section on 'Recommendations for ICD therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4932.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Treatment and prognosis"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4924.html" rel="external">"Isolated left ventricular noncompaction in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/106760.html" rel="external">"Brugada syndrome or pattern: Management and approach to screening of relatives"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/988.html" rel="external">"Congenital long QT syndrome: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H362963127"><span class="h1">CAUSES OF DEATH IN HEART FAILURE</span><span class="headingEndMark"> — </span>Causes of death in patients with heart failure include:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive pump failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexpected SCD (usually from a ventricular tachyarrhythmia, but asystole and pulseless electrical activity [PEA] are also seen less frequently).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SCD in the setting of worsening heart failure.</p><p></p><p>The mode of death in patients with HF is more likely to be "sudden" in patients with class II or III HF, while the mode of death is more likely to be related to "pump" failure in patients with class IV HF  (<a class="graphic graphic_figure graphicRef98258" href="/z/d/graphic/98258.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. Therefore, primary prevention implantable cardioverter-defibrillator (ICD) trials (in the absence of cardiac resynchronization therapy [CRT]) have excluded patients with NYHA class IV HF. In fact, the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) Guidelines state that "ICD therapy is not indicated for NYHA Class IV patients with medication-refractory HF who are not also candidates for cardiac transplantation, an LVAD (left ventricular assist device), or CRT-D," listing this as a class III indication [<a href="#rid2">2</a>]. (See <a class="local">'Class IV heart failure'</a> below and  <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a> and  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.) </p><p class="headingAnchor" id="H547145912"><span class="h1">RISK STRATIFICATION STRATEGIES</span><span class="headingEndMark"> — </span>While implantable cardioverter-defibrillators (ICDs) are highly efficacious in the treatment of ventricular tachyarrhythmias and prevention of SCD, they are costly, require ongoing follow-up, and have numerous risks at the time of implantation (eg, bleeding, pneumothorax, perforation, etc) as well as over the lifetime of the device (eg, infection, device and lead malfunction, etc). In addition, only a subset of patients with cardiomyopathy develop sustained ventricular tachyarrhythmias or SCD. As such, the risk stratification of patients prior to ICD therapy is important for providing therapy to patients at highest risk of SCD and minimizing the number of ICD implantations in patients who are unlikely to benefit.</p><p>Numerous patient-related clinical markers as well as data derived from testing have been associated with increased risk of sudden death, and a variety of attempts have been made to develop risk stratification schema to more specifically identify an individual patient's risk of SCD. To date, however, the optimal approach to SCD risk stratification for placement of a primary prevention ICD continues to rely primarily upon the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Etiology of left ventricular dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular ejection fraction</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure symptom classification</p><p class="bulletIndent1"><span class="glyph">●</span>Life expectancy greater than one year </p><p class="bulletIndent1"><span class="glyph">●</span>Inducible sustained ventricular tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsustained ventricular tachycardia on electrocardiogram (ECG) monitoring</p><p></p><p class="headingAnchor" id="H443579776"><span class="h2">LVEF and risk</span><span class="headingEndMark"> — </span>Patients with significant reductions in left ventricular ejection fraction (LVEF) appear to be at greatest risk, and derive the greatest benefit, from primary prevention ICD implantation. (See <a class="local">'Trials of primary prevention ICDs in ischemic cardiomyopathy'</a> below and <a class="local">'Trials of primary prevention ICDs in nonischemic dilated cardiomyopathy'</a> below.)</p><p>Though most studies of prophylactic ICD implantation have included patients with an LVEF ≤35 percent, the large majority of patients included in most trials have had ejection fractions under 30 percent, resulting in some uncertainty regarding the potential benefit of prophylactic ICD insertion for patients with LVEF between 30 and 35 percent. This issue was addressed in a retrospective cohort study using registry data from the NCDR ICD registry of patients who underwent ICD implantation in 2006 or 2007 (median follow-up 4.4 years) and Get With The Guidelines-Heart Failure (GWTG-HF) patients without an ICD (enrolled between 2005 and 2009 with median follow-up of 2.9 years), in which the benefits of ICD implantation were separately evaluated among patients with LVEF &lt;30 percent and those with LVEF 30 to 35 percent [<a href="#rid3">3</a>]. All-cause mortality was significantly lower in patients with an ICD and any level of LVEF, compared with those without an ICD:</p><p class="bulletIndent1"><span class="glyph">●</span>LVEF 30 to 35 percent – hazard ratio (HR) 0.83, 95% CI 0.69-0.99</p><p class="bulletIndent1"><span class="glyph">●</span>LVEF &lt;30 percent – HR 0.72, 95% CI 0.65-0.81</p><p></p><p>While this study is nonrandomized, the data suggest that patients with LVEF between 30 and 35 percent do appear to benefit from prophylactic ICD insertion.</p><p class="headingAnchor" id="H547145918"><span class="h2">SCD risk prediction post-MI</span><span class="headingEndMark"> — </span>A number of clinical features have been evaluated as a means for identifying patients at the greatest risk of SCD following an acute myocardial infarction (MI). These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular (LV) dysfunction or reduced LVEF</p><p class="bulletIndent1"><span class="glyph">●</span>HF symptoms and the degree of heart failure </p><p class="bulletIndent1"><span class="glyph">●</span>LV aneurysm </p><p class="bulletIndent1"><span class="glyph">●</span>Q-waves on the surface ECG</p><p class="bulletIndent1"><span class="glyph">●</span>Intraventricular conduction delay</p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous ventricular premature beats (VPBs) and nonsustained ventricular tachycardia (NSVT)</p><p class="bulletIndent1"><span class="glyph">●</span>Late potentials on a signal-averaged ECG (SAECG)</p><p class="bulletIndent1"><span class="glyph">●</span>VT induced by electrophysiologic study (EPS)</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced heart rate variability (HRV)</p><p class="bulletIndent1"><span class="glyph">●</span>Microvolt T-wave (repolarization) alternans (TWA)</p><p></p><p>A detailed discussion of the utility of these clinical predictors is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p class="headingAnchor" id="H2276208583"><span class="h3">Clinical risk markers</span><span class="headingEndMark"> — </span>A variety of novel risk stratification schemes derived from retrospective studies have shown the ability to predict SCD risk, but none have been prospectively validated in independent populations or have become part of the routine practice for primary prevention ICD placement [<a href="#rid4">4-13</a>]. Therefore, traditional risk stratification based on etiology of cardiomyopathy, LVEF, HF class, and select other risk markers (eg, inducible sustained ventricular arrhythmias) continues to form the basis for recommendations regarding ICD use.</p><p>Initial studies evaluating the role of ICD therapy in reducing mortality focused on patients with reduced LV systolic function and class II-III heart failure. As the mode of death in patients with class II-III heart failure was more likely sudden (in 59 to 64 percent of cases [<a href="#rid1">1</a>]), and enrollment criteria for ICD trials often included patients with class II-III HF symptoms. In contrast, patients with class IV heart failure were more likely to die from heart failure (56 percent) than from sudden death (33 percent). Studies examining the relationship between one-year mortality and LV function after MI in the pre- and post-thrombolytic era demonstrated a much higher cardiac mortality rate in patients with LVEF &lt;40 percent [<a href="#rid14">14,15</a>]. The presence of NSVT or frequent ventricular ectopy was also associated with increased mortality post-MI, so NSVT was also used as a risk factor for inclusion in some of the randomized ICD trials. Earlier studies also demonstrated that inducible sustained monomorphic VT was associated with an increased risk of sudden death or sustained ventricular arrhythmias [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H935487333"><span class="h3">Myocardial fibrosis on CMR</span><span class="headingEndMark"> — </span>The presence of myocardial fibrosis, identified by late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging appears to be a robust predictor of ventricular arrhythmias or SCD across a wide spectrum of patients with non-ischemic cardiomyopathy, including those with a mean LVEF &gt;35 percent. </p><p class="bulletIndent1"><span class="glyph">●</span>A 2017 systematic review and meta-analysis, which included 2948 patients from 29 observational studies, assessed the relationship between LGE and ventricular arrhythmias in patients with non-ischemic dilated cardiomyopathy [<a href="#rid17">17</a>]. Over a mean follow-up of three years, the primary endpoint (sustained ventricular arrhythmia, appropriate ICD intervention, or SCD) occurred in 350 patients, including 21 percent of patients with LGE (compared with 4.7 percent of patients without LGE; pooled odds ratio [OR] 4.3, 95% CI 3.3-5.8). LGE was able to risk stratify patients at all levels of LVEF (both above and below 35 percent) and was most powerful among patients with ICDs previously placed for primary prevention (OR 7.8, 95% CI 1.7-35.8). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2019 Australian prospective, nonrandomized study of 452 patients with non-ischemic cardiomyopathy (LVEF ≤35 percent) who had all undergone CMR imaging and who met ESC/AHA criteria for primary prevention ICD placement, half received a primary prevention ICD according to the judgment of the treating physician and prevailing local practice [<a href="#rid18">18</a>]. Patients with myocardial fibrosis (manifest by LGE on CMR imaging) who received an ICD had lower mortality than those who did not get an ICD (HR 0.45, 95% CI 0.26-0.77). However, there was no difference in survival with or without an ICD for the 175 patients without myocardial fibrosis. </p><p></p><p>The MARVEN (Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy) Study is an NHLBI-sponsored prospective, observational study aimed at developing optimal risk stratification strategies to predict ventricular tachyarrhythmias in patients with nonischemic cardiomyopathy undergoing CRT-D implantation to determine whether LGE-CMR will further improve risk stratification in patients with nonischemic cardiomyopathy, LVEF ≤35 percent, and QRS ≥120 milliseconds [<a href="#rid19">19</a>]. While not currently utilized in SCD risk stratification guidelines, if these data are confirmed in additional prospective studies, then LGE on CMR may become a criterion used in future risk stratification schemes.</p><p class="headingAnchor" id="H14874389"><span class="h1">USE OF AN ICD</span><span class="headingEndMark"> — </span>Malignant ventricular arrhythmias potentially leading to SCD are more frequently seen in patients with certain cardiomyopathies (compared with the general population), particularly in association with heart failure (HF) symptoms. As in secondary prevention, randomized clinical trials have established a clear role for primary prevention implantable cardioverter-defibrillators (ICDs) in selected patients  (<a class="graphic graphic_table graphicRef98261" href="/z/d/graphic/98261.html" rel="external">table 1</a>). In contrast, antiarrhythmic drugs other than beta blockers do not appear to improve outcomes. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p>The role of an ICD in the primary prevention of SCD among patients with HF and cardiomyopathy depends upon several factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The severity of left ventricular (LV) systolic dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The severity of clinical HF  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The etiology of LV dysfunction (ie, ischemic or nonischemic cardiomyopathy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Competing co-morbidities that affect longevity and risk of ICD complications (eg, chronic kidney disease, chronic obstructive pulmonary disease, etc).</p><p></p><p>The risk of SCD increases with the severity of both LV systolic dysfunction and clinical HF [<a href="#rid20">20</a>]. However, the risk of death due to other causes (eg, progressive HF) also increases with worsening HF and LV systolic dysfunction, reinforcing the importance of appropriate patient selection prior to primary prevention ICD placement. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Epidemiology'</a>.)</p><p>Cardiac resynchronization therapy (CRT) may be appropriate treatment for selected patients with HF with ischemic or non-ischemic cardiomyopathy and reduced left ventricular ejection fraction (LVEF) (≤35 percent) with a wide QRS complex (especially if left bundle branch block QRS morphology), if left ventricular function does not improve with guideline-directed medical therapy. Ventricular dyssynchrony refers to the loss of coordinated contraction across the left ventricle. Dyssynchrony can further impair the pump function of a failing ventricle and exacerbate HF symptoms. CRT can improve pump performance, reverse the deleterious process of ventricular remodeling, and improve survival in appropriately selected patients. CRT can be achieved with a device designed for pacing only (CRT-P) or can be incorporated into a combination device with an ICD (CRT-D)  (<a class="graphic graphic_figure graphicRef79450" href="/z/d/graphic/79450.html" rel="external">figure 2</a>) [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p class="headingAnchor" id="H362963650"><span class="h2">Ischemic cardiomyopathy</span></p><p class="headingAnchor" id="H1363471577"><span class="h3">Our approach for patients with ischemic cardiomyopathy</span><span class="headingEndMark"> — </span>We recommend ICD therapy for primary prevention of SCD in the following groups of patients with ischemic cardiomyopathy: </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cardiomyopathy due to ischemic heart disease, left ventricular ejection fraction (LVEF) ≤35 percent, and associated HF with New York Heart Association (NYHA) functional class II or III status [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cardiomyopathy due to ischemic heart disease, LVEF ≤30 percent, and NYHA functional class I status [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In both instances, patients should be at least 40 days post-myocardial infarction (MI) and more than three months following revascularization and taking guideline-directed medical therapy. These restrictions recognize that revascularization and medical therapy may result in significant improvement in LVEF and/or HF class.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with nonsustained ventricular tachycardia (NSVT) associated with prior MI, LVEF ≤40 percent, and inducible sustained VT or ventricular fibrillation at electrophysiology study [<a href="#rid2">2,22,23</a>]. Patients should be past the acute phase of MI, on guideline-directed medical therapy, and have reasonable expectation for survival for at least one year.</p><p></p><p>Patients who have had an MI resulting in reduced LVEF are at increased risk of SCD, most often due to a ventricular tachyarrhythmia. Prophylactic ICD implantation for the primary prevention of SCD reduces mortality in selected patients with ischemic cardiomyopathy. Coronary revascularization itself may also reduce the future risk of malignant arrhythmias and SCD, as shown in the early versus late ICD implantation strategies and differing results in various randomized trials. The best approach to selecting patients with ischemic cardiomyopathy for ICD therapy for primary prevention has been explored in several major randomized trials, with the indications for ICD implantation derived largely from the inclusion criteria of these trials. One caveat, however, is that these trials took place prior to the contemporary guideline-based approaches to optimal medical therapy for patients with heart failure and cardiomyopathy.</p><p class="headingAnchor" id="H1066229284"><span class="h3">Trials of primary prevention ICDs in ischemic cardiomyopathy</span></p><p class="headingAnchor" id="H2336568583"><span class="h4">MADIT-I trial</span><span class="headingEndMark"> — </span>The Multicenter Automatic Defibrillator Implantation Trial (MADIT, now called MADIT-I) was the first trial to demonstrate that the ICD has a role in primary prevention of SCD in certain high-risk, asymptomatic patients [<a href="#rid22">22</a>]. Patients had a prior MI with reduced LVEF (≤35 percent), NSVT on ECG monitoring, and inducible sustained monomorphic VT during electrophysiology study (EPS) that was also inducible after administration of intravenous <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>. Among 196 patients who were randomly assigned to pharmacologic therapy (including an antiarrhythmic drug at the discretion of the clinician, with <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> administered to most patients) or an ICD and followed for an average of 27 months, patients assigned to ICD therapy had significant reductions in overall mortality, cardiac mortality, and arrhythmic deaths compared with patients assigned to medical therapy  (<a class="graphic graphic_figure graphicRef76854" href="/z/d/graphic/76854.html" rel="external">figure 3</a>). While the MADIT-I trial remains an important landmark study in the utilization of ICDs for primary prevention, it has largely been supplanted by subsequent studies with larger numbers of patients, better methodologies, and simpler risk stratification schemes for study entry.</p><p class="headingAnchor" id="H2873105807"><span class="h4">MUSTT trial</span><span class="headingEndMark"> — </span>The Multicenter Unsustained Tachycardia Trial (MUSTT trial), which was not primarily designed as a randomized ICD clinical trial but rather to study the management of high-risk patients using the results of electrophysiology study (EPS), enrolled patients with prior MI, reduced LVEF (≤40 percent), asymptomatic NSVT on ECG monitoring, inducible sustained VT during EPS, and no history of VT or syncope [<a href="#rid23">23</a>]. A total of 704 patients were randomly assigned to either standard medical therapy (353 patients) or EPS-guided antiarrhythmic therapy, which included either an antiarrhythmic agent (154 patients received a class IA drug with or without <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">mexiletine</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, or <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>) or an ICD (161 patients) if at least one antiarrhythmic agent was ineffective. After a median follow-up of 39 months, the five-year (25 versus 32 percent, relative risk [RR] 0.73, 95% CI 0.53-0.99) rates for the primary endpoint (arrhythmic death or resuscitated SCD) were significantly lower for EPS-guided therapy compared with standard medical therapy. The reduction in the primary endpoint in the EPS-guided group was largely attributable to ICD therapy; at five years, the primary endpoint occurred in 9 percent of those receiving an ICD, compared with 37 percent of those receiving an antiarrhythmic drug (RR 0.24, 95% CI 0.13-0.45)  (<a class="graphic graphic_figure graphicRef68247" href="/z/d/graphic/68247.html" rel="external">figure 4</a>).</p><p>Whether inducible arrhythmia might be prognostically important in patients with an LVEF of 30 to 40 percent was addressed in another analysis from MUSTT [<a href="#rid24">24</a>]. The rate of arrhythmic death at five years was significantly increased for patients with inducible VT and LVEF between 30 and 40 percent, suggesting that for patients with LVEF ≥30 percent only, electrophysiology testing may have useful predictive value. </p><p class="headingAnchor" id="H2713754544"><span class="h4">CABG Patch trial</span><span class="headingEndMark"> — </span>The Coronary Artery Bypass Graft (CABG) Patch trial evaluated the efficacy of an epicardial ICD implanted at the time of coronary artery bypass graft surgery among 900 patients with severe coronary artery disease (CAD), reduced LVEF &lt;36 percent, abnormal signal averaged ECG, and no prior sustained VT or syncope [<a href="#rid25">25</a>]. Epicardial ICD systems were predominantly used. Compared with standard medical therapy over an average of 32 months, there was no significant difference in overall or cardiovascular mortality among patients with an ICD (hazard ratio [HR] 1.07 for overall mortality compared with standard medical therapy, 95% CI 0.81-1.42)  (<a class="graphic graphic_figure graphicRef78888" href="/z/d/graphic/78888.html" rel="external">figure 5</a>). This negative trial is a primary reason why current guidelines recommend against primary prevention ICD implantation for patients who have recently undergone coronary revascularization, as revascularization itself may reduce the future risk of malignant arrhythmias and SCD. </p><p class="headingAnchor" id="H2636212450"><span class="h4">MADIT-II trial</span><span class="headingEndMark"> — </span>The Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) enrolled 1232 patients with a prior MI more than 30 days prior to enrollment (and more than three months if bypass surgery was performed) and reduced LVEF (≤30 percent); NSVT and inducible VT during EPS were not required [<a href="#rid26">26</a>]. The study, which randomly assigned patients to a prophylactic ICD or conventional medical therapy, was stopped early due to benefit of ICD therapy after an average follow-up of 20 months. Patients in the ICD group had reduced all-cause mortality (14.2 versus 19.8 percent for conventional therapy; HR 0.65, 95% CI 0.51-0.93)  (<a class="graphic graphic_figure graphicRef63529" href="/z/d/graphic/63529.html" rel="external">figure 6</a>). </p><p class="headingAnchor" id="H333971530"><span class="h4">SCD-HeFT trial</span><span class="headingEndMark"> — </span>The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which evaluated ICD and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> therapies in patients with both ischemic (52 percent) or nonischemic (48 percent) cardiomyopathy, enrolled patients with the following criteria [<a href="#rid27">27</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>NYHA class II or III HF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced LVEF (&lt;35 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congestive heart failure (CHF) present for at least three months prior to randomization and treated with ACE inhibitor and beta blocker, if tolerated.</p><p></p><p>Among 2521 patients who were randomly assigned to ICD implantation, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, or placebo, and followed for a median of 46 months, total mortality at five years was significantly reduced with ICD therapy (29 versus 36 percent with placebo; HR 0.77, 95% CI 0.62-0.96). The benefit of an ICD was comparable among patients with either an ischemic or nonischemic cardiomyopathy. A long-term analysis of SCD-HeFT participants, published in July 2020, showed continued survival benefit in the ICD arm over placebo arm at a median follow-up of 11 years (HR 0.87, 95% CI 0.76-0.98) [<a href="#rid28">28</a>]. Long-term benefit was most evident for patients with ischemic cardiomyopathy and those with NYHA functional class II symptoms at enrollment.</p><p>These results suggest that an ICD is beneficial in patients with chronic HF and a diminished LVEF (≤35 percent), despite appropriate medical therapy for at least three months. In contrast, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> provided no benefit over placebo. </p><p class="headingAnchor" id="H3912015404"><span class="h4">DINAMIT trial</span><span class="headingEndMark"> — </span>The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), which evaluated the role of prophylactic ICD implantation compared with standard medical therapy, enrolled 674 patients with MI in the preceding 6 to 40 days (mean of 18 days), reduced LVEF (≤35 percent), and reduced heart rate variability or elevated resting heart rate (≥80 beats/minute) [<a href="#rid29">29</a>]. Patients with sustained VT &gt;48 hours post-MI, NYHA class IV HF, or CABG or three-vessel percutaneous coronary intervention post-MI were excluded. After a mean follow-up of 30 months, there was no significant difference in annual all-cause mortality between the patients with and without an ICD (7.5 versus 6.9 percent annual mortality; HR 1.08, 95% CI 0.76-1.55). This negative trial provides an important rationale for the current guideline recommendation that ICD implantation should be deferred until at least 40 days after an MI. </p><p class="headingAnchor" id="H3424817621"><span class="h4">IRIS trial</span><span class="headingEndMark"> — </span>The Immediate Risk Stratification Improves Survival (IRIS) trial also evaluated the efficacy of ICD therapy versus standard therapy early post-MI and enrolled patients with an MI in the preceding 5 to 31 days <strong>and</strong> at least one of the following: reduced LVEF (≤40 percent) with a resting heart rate ≥90 beats/minute <strong>or</strong> NSVT at a rate of ≥150 beats/minute <strong>or</strong> both [<a href="#rid30">30</a>]. Among 898 randomized patients who were followed for an average of 37 months, there was no difference in all-cause mortality between patients randomly assigned to ICD therapy and those assigned to medical therapy (HR 1.04 for ICD therapy, 95% CI 0.81-1.35). </p><p class="headingAnchor" id="H14874407"><span class="h2">Nonischemic dilated cardiomyopathy</span></p><p class="headingAnchor" id="H2259784163"><span class="h3">Our approach for patients with nonischemic dilated cardiomyopathy</span><span class="headingEndMark"> — </span>We recommend ICD therapy for primary prevention of SCD in the following groups of patients with nonischemic dilated cardiomyopathy:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients meeting SCD-HeFT criteria, including an LVEF ≤35 percent and NYHA class II to III  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>) HF, we suggest ICD implantation rather than guideline-directed optimal medical therapy alone [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with LVEF ≤35 percent, class III or IV HF, and a QRS duration ≥120 milliseconds (especially if left bundle branch block [LBBB] QRS morphology), we recommend implantation of a combined CRT-D device (biventricular pacing combined with an ICD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additionally, many patients with specific non-ischemic cardiomyopathies (eg, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, cardiac amyloidosis, etc) may be candidates for primary prevention ICD based on disease-specific risk markers. The approaches to selection of appropriate patients in a variety of conditions are discussed in the individual UpToDate topics.</p><p></p><p>Ventricular arrhythmias are common in patients with HF and a nonischemic cardiomyopathy. While some small early trials suggested no benefit of ICD therapy in patients with nonischemic cardiomyopathy, subsequent larger trials and a 2004 meta-analysis have demonstrated greater overall survival following prophylactic ICD implantation in selected patients. While ICDs effectively reduce mortality from SCD, the benefit on total mortality appears diminished in the setting of optimal guideline-directed medical therapy and CRT. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H347764821"><span class="h3">Trials of primary prevention ICDs in nonischemic dilated cardiomyopathy</span></p><p class="headingAnchor" id="H4214756399"><span class="h4">DEFINITE trial</span><span class="headingEndMark"> — </span>The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial evaluated the efficacy of an ICD versus standard medical therapy, in 458 patients with nonischemic dilated cardiomyopathy, reduced LVEF (≤35 percent), and premature ventricular beats or NSVT [<a href="#rid31">31</a>]. After mean follow-up of 29 months, there was a trend toward reduction in the primary endpoint of all-cause mortality in patients treated with an ICD (7.9 versus 14.1 percent with medical therapy alone; HR 0.65, 95% CI 0.40-1.06). Fewer sudden deaths occurred in the ICD arm, although the numbers were very small (3 deaths versus 14 deaths in the medical therapy arm; HR 0.20, 95% CI 0.06-0.71). The all-cause mortality rate in the "medical therapy only" arm of DEFINITE (14.1 percent at two years) was lower than had been anticipated when the study was designed, potentially contributing to the trial being underpowered for its primary endpoint.</p><p class="headingAnchor" id="H2659097771"><span class="h4">SCD-HeFT trial</span><span class="headingEndMark"> — </span>The Sudden Cardiac Death in Heart Failure trial (SCD-HeFT), which evaluated ICD and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> therapies in patients with both ischemic (52 percent) or nonischemic (48 percent) cardiomyopathy, identified a significant reduction in overall mortality with ICD therapy (29 versus 36 percent with placebo; HR 0.77, 95% CI 0.62-0.96) [<a href="#rid27">27</a>]. The benefit of an ICD was comparable among patients with either an ischemic or nonischemic cardiomyopathy. (See <a class="local">'Trials of primary prevention ICDs in ischemic cardiomyopathy'</a> above.)</p><p class="headingAnchor" id="H2324685635"><span class="h4">COMPANION trial of ICD combined with CRT</span><span class="headingEndMark"> — </span>For most patients with LVEF ≤35 percent, class III or IV HF, and a QRS duration ≥120 milliseconds, we recommend implantation of a combined CRT-D device (biventricular pacing combined with an ICD) [<a href="#rid32">32,33</a>]. The benefit appears to be greatest in patients with a left bundle branch block and QRS duration ≥150 milliseconds [<a href="#rid34">34-36</a>]. Patients with right bundle branch block and a QRS duration &lt;150 ms are much less likely to benefit from CRT.</p><p>The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial evaluated optimal medical therapy versus CRT with or without an ICD among 682 patients with nonischemic dilated cardiomyopathy, reduced LVEF (≤35 percent), and NYHA class III or IV HF symptoms requiring hospitalization within the prior year [<a href="#rid33">33</a>]. After median follow-up of 16 months, there was a significant reduction in the incidence of the combined endpoint of all-cause mortality and all-cause hospitalization in the two arms receiving CRT compared with the medical therapy only arm (56 versus 68 percent). The CRT-D arm, but not the CRT-P arm, experienced a significant improvement in the secondary endpoint of all-cause mortality alone.</p><p class="headingAnchor" id="H577020894"><span class="h4">DANISH trial</span><span class="headingEndMark"> — </span>The Danish Study to Assess the Efficacy of ICDs in Patients with Non-Ischemic Systolic Heart Failure on Mortality (DANISH) randomly assigned 1116 patients with symptomatic systolic HF (LVEF ≤35 percent) not caused by ischemic heart disease to an ICD with guideline-directed optimal medical therapy or medical therapy alone [<a href="#rid37">37</a>]. Over a median follow-up of 5.6 years, no significant difference was noted in the primary outcome of total mortality (120 deaths [21.6 percent] in the ICD group compared with 131 deaths [23.4 percent] in the group without an ICD; HR 0.87, 95% CI 0.68-1.12). A significant reduction was noted in the prespecified secondary outcome of SCD in the group receiving ICDs (24 deaths [4.3 percent] compared with 46 sudden deaths [8.2 percent] in the no ICD group; HR 0.50, 95% CI 0.31-0.82), as well as nonsignificant trends toward reduction in total cardiovascular mortality and increased device infections in the ICD group.</p><p>Compared with prior primary prevention ICD trials, the overall mortality rate of patients in the DANISH trial was low, likely due to improved medical therapy for HF (notably a much higher utilization of ACE-I/ARB and beta blockers than in the older trials) and the use of CRT, which was not available during the older primary prevention trials. Because of this, the DANISH trial may have been underpowered to show a mortality benefit of ICD therapy. Finally, as there are competing causes of death with increasing age, one might not expect the same benefit of ICD therapy in older patients, who may have greater comorbidities which could contribute to nonarrhythmic causes of death. Our experts feel that it would be premature to use data from the DANISH study as the sole basis to withhold potentially life-saving ICD therapy from all patients with nonischemic cardiomyopathy. Instead, the results actually support the use of ICDs in younger patients who have a cardiomyopathy not caused by ischemic heart disease. For those patients who are likely to have a strong response to CRT or who are not considered good candidates for ICD therapy, a CRT-P device may be more suitable and compatible with therapeutic goals. </p><p class="headingAnchor" id="H1227411973"><span class="h4">Meta-analyses of ICD trials in nonischemic cardiomyopathy</span><span class="headingEndMark"> — </span>Several updated meta-analyses have been published that include patients with nonischemic cardiomyopathy receiving an ICD for primary prevention from the same original five ICD trials (CAT, AMIOVIRT, DEFINITE, SCD-HeFT, and COMPANION) as well as patients from the DANISH trial [<a href="#rid38">38-46</a>]. When considering all six trials collectively, each of the meta-analyses demonstrated a significant benefit of the ICD on all-cause mortality in patients with nonischemic cardiomyopathy (19 to 24 percent hazard reduction compared with medical therapy alone). When only patients who also received CRT in the COMPANION and DANISH trials were analyzed, there was a nonsignificant trend toward reduction in all-cause mortality among patients with an ICD (approximately 25 to 30 percent hazard reduction with nonsignificant confidence intervals) [<a href="#rid38">38,40,43</a>]. Despite the lack of a significant incremental benefit of the ICD in the two trials that included CRT, it is currently premature to withhold ICD therapy in all patients with nonischemic cardiomyopathy who require concomitant CRT. Adequately powered randomized studies are needed before recommending a change in current practice guidelines. </p><p class="headingAnchor" id="H547147053"><span class="h1">GUIDELINE-DIRECTED MEDICAL THERAPY</span><span class="headingEndMark"> — </span>For patients who meet criteria for insertion of an implantable cardioverter-defibrillator (ICD) for the primary prevention of SCD, in the absence of a contraindication, we recommend optimizing guideline-directed medical therapy <strong>prior</strong> to ICD implantation. </p><p class="headingAnchor" id="H1913648121"><span class="h2">Heart failure therapy</span><span class="headingEndMark"> — </span>Several of the components of appropriate medical therapy after a myocardial infarction (MI) reduce SCD as well as overall mortality. While these data are derived from trials in patients with ischemic heart disease, we can infer that many of the same benefits should apply to SCD risk reduction in patients with nonischemic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – In addition to reducing overall mortality in patients with an acute MI, beta blockers also reduced the risk of SCD [<a href="#rid47">47,48</a>]. The SCD benefit is better established in patients with chronic HF. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a> and  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy", section on 'Heart failure therapy'</a>.)</p><p></p><p class="bulletIndent1">Patients who are post-MI with an ICD also appear to derive a benefit from beta blockers. In a cohort of 691 patients with ischemic cardiomyopathy who received an ICD in the MADIT-II trial, the 433 patients treated with a beta blocker had significantly lower mortality (hazard ratio [HR] 0.43) compared with those not taking beta blockers; additionally, patients in the highest quartile of beta blocker dose had a significant reduction in the risk of ventricular tachyarrhythmias requiring ICD discharge (HR 0.48) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors</strong> – A meta-analysis of 15,104 patients in 15 trials of acute MI found that angiotensin-converting enzyme (ACE) inhibitor therapy reduced the risk of SCD (odds ratio 0.80, 95% CI 0.70-0.92, absolute benefit approximately 1.4 percent) as well as overall and cardiovascular mortality [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/71.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin II receptor blockers</strong> – Angiotensin II receptor blockers (ARBs) are often used for patients who cannot tolerate ACE inhibitors. At appropriate doses, it is likely that ARBs reduce the risk of SCD to the same degree as ACE inhibitors [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin receptor-neprilysin inhibitor</strong> – The combination of an ARB and neprilysin inhibitor, known as angiotensin receptor-neprilysin inhibitor or ARNI, is another therapy for use in patients with HF and reduced LVEF (HFrEF). A randomized double-blind trial (PARADIGM-HF) in patients with HFrEF found that <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> reduced cardiovascular mortality and hospitalization for HF as well as all-cause mortality compared with a standard dose of the ACE inhibitor <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> [<a href="#rid52">52</a>]. The ARNI combination is administered in conjunction with other HF therapies, in place of an ACE inhibitor or ARB. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Primary components of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Statins given to patients who have had an acute MI improve overall mortality. Although data are limited and inconclusive, part of the benefit may result from a lower rate of SCD, which may reflect a direct effect of statin therapy [<a href="#rid53">53-55</a>]. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mineralocorticoid receptor antagonists</strong> – Among patients who are post-MI who have left ventricular (LV) dysfunction and HF and/or diabetes, <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a> significantly reduced both overall mortality and SCD (relative risk for SCD 0.79, 95% CI 0.64-0.97) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p></p><p class="bulletIndent1"><strong>Sodium–glucose co-transporter 2 inhibitors (SGLT-2 inhibitors)</strong> – Evidence as to whether SGLT-2 inhibitors reduced SCD and/or ventricular arrhythmias in patients with HF is mixed and has not been directly studied. In a post-hoc analysis of the DAPA-HF trial of persons with New York Heart Association (NYHA) class II to IV HF and LVEF &lt;40 percent, the SGLT-2 inhibitor <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> reduced occurrence of the composite outcome of any serious ventricular arrhythmia, resuscitated cardiac arrest, or sudden death compared with placebo [<a href="#rid57">57</a>]. Among participants randomized to dapagliflozin, 140 of 2373 patients (5.9 percent) experienced the composite outcome compared with 175 of 2371 patients (7.4 percent) in the placebo group (HR 0.79, 95% CI 0.63-0.99). The effect was consistent across each of the composite outcome components. While a prior meta-analysis of 34 randomly controlled trials in participants with type 2 diabetes mellitus or HF also showed that SGLT-2 inhibitors reduced SCD compared with placebo or active control (OR 0.72 95% CI 0.54-0.97), this result just achieved statistical significance, and there was no significant difference in incident ventricular arrhythmia or cardiac arrest [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'</a>.) </p><p></p><p>Despite the proven benefits, some patients are not receiving guideline-directed medical therapy at the time of ICD implantation. In a 2011 study analyzing 175,757 first-time ICD recipients, using data from the National Cardiovascular Data Registry, 25.7 percent of ICD recipients without a documented contraindication were reported as not receiving optimal medical therapy at the time of ICD implantation, including 18.7 percent who were reported as not receiving an ACE inhibitor or ARB and 10.7 percent who were reported as not receiving a beta blocker [<a href="#rid59">59</a>]. While some of these gaps may reflect issues of coding and documentation, these data suggest an opportunity for significant improvement in the treatment of patients with evidence-based, cost-effective therapies that could potentially result in improvement in cardiomyopathy and avoidance of an ICD. Although current guidelines suggest at least three months of guideline-directed medical therapy in patients with symptomatic HF and left ventricular ejection fraction (LVEF) ≤35 percent, the ideal duration of guideline-directed medical therapy prior to prophylactic ICD implantation remains uncertain. However, data demonstrate that a relevant proportion of patients with newly diagnosed HF may show recovery of LVEF &gt;35 percent beyond three months after initiation of HF therapy, allowing left ventricular reverse remodeling to occur during intensified treatment [<a href="#rid60">60</a>]. </p><p class="headingAnchor" id="H547145563"><span class="h2">Antiarrhythmic drugs</span><span class="headingEndMark"> — </span>Randomized clinical trials do <strong>not</strong> support the routine use of prophylactic antiarrhythmic drug therapy, other than beta blockers, to prevent SCD in patients with HF [<a href="#rid1">1,61-64</a>]. The lack of overall benefit from prophylactic antiarrhythmic drug therapy is due to both incomplete suppression of ventricular arrhythmias and the risk of proarrhythmia [<a href="#rid62">62,63,65-69</a>]. Given the established superiority of an ICD in high-risk patients, class I and class III antiarrhythmic drugs no longer have an established role for the primary prevention of SCD.</p><p>Among the antiarrhythmic drugs, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> has the advantage of a relatively low rate of proarrhythmia, less negative inotropic effect, and higher efficacy for suppression of tachyarrhythmias. While amiodarone is not approved for use in the primary prevention of arrhythmias, this was a common off-label use of the drug [<a href="#rid22">22</a>]. In addition, amiodarone is frequently used for the treatment of atrial fibrillation as it is considered relatively "safe," from a cardiac standpoint, with low risk for proarrhythmia in the setting of HF [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Antiarrhythmic drugs'</a> and  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Amiodarone for ventricular arrhythmias'</a>.)</p><p class="headingAnchor" id="H539451534"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H14874533"><span class="h2">Class IV heart failure</span><span class="headingEndMark"> — </span>Class IV HF is a state that may be transitory and therefore associated with heterogeneous prognosis. Once class IV HF is refractory (stage D HF), life expectancy is generally less than one year unless cardiac transplantation is performed or a left ventricular assist device is implanted. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Cardiac transplantation'</a>.)</p><p>The role of implantable cardioverter-defibrillator (ICD) therapy for primary prevention of SCD in patients with New York Heart Association (NYHA) class IV HF with a narrow QRS complex has not been studied. NYHA class IV patients were generally excluded from randomized primary prevention ICD trials due to high expected mortality rate from pump failure, and only a small number were included in cardiac resynchronization therapy combined with ICD (CRT-D) trials. However, a nonrandomized series of patients awaiting cardiac transplantation suggested a higher likelihood of survival to transplantation with ICD therapy, regardless of whether the ICD indication was well established [<a href="#rid71">71</a>].</p><p>Given these considerations, for ambulatory patients with NYHA class IV HF, a left ventricular ejection fraction (LVEF) ≤35 percent and a narrow QRS complex (ie, no dyssynchrony), who are awaiting cardiac transplantation outside the hospital, ICD implantation may be considered as a bridge to transplantation. However, there are very limited data to support this recommendation [<a href="#rid2">2,71</a>]. According to the 2017 Guideline for the Management of Patients with Ventricular Arrhythmias, "in patients with HFrEF who are awaiting heart transplant and who otherwise would not qualify for an ICD (eg, NYHA class IV and/or use of inotropes) with a plan to discharge home, an ICD is reasonable (class IIa recommendation, B-NR)." A wearable defibrillator vest may be considered as an alternative in selected patients [<a href="#rid72">72,73</a>]. </p><p class="headingAnchor" id="H14874545"><span class="h2">Older adults and patients with comorbidities</span><span class="headingEndMark"> — </span>Because of the competing risks of arrhythmic and nonarrhythmic death, some investigators have expressed concern that older adults and those with multiple or severe comorbidities might be less likely to derive benefit from an ICD [<a href="#rid74">74-77</a>]. The mean age of patients in randomized primary prevention ICD trials ranged from 60 to 67 years, and patients over 75 to 80 years comprised a relatively small proportion of these cohorts. Because most older adult patients as well as those patients with severe comorbidities (such as advanced kidney disease) were excluded from most of the major ICD trials, the survival benefit from ICD implantation in such populations is less well defined. The decision to recommend an ICD should be made on a case-by-case basis based on shared decision-making, taking into account patient values and preferences. Age or comorbidity alone should not be a sole exclusion for ICD implantation.</p><p>As part of the 2017 AHA/ACC/HRS guideline for management of ventricular arrhythmias and prevention of SCD, a systematic review was performed to specifically assess the impact of primary prevention ICD therapy among older patients and patients with significant morbidities [<a href="#rid78">78</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older adults</strong> – While the systematic review identified 10 studies of primary prevention ICD use among older adults, because of concerns about overlapping patients between some of the studies, the final "minimal overlap" meta-analysis included four studies with unique patient populations. Compared with patients without ICD implantation, patients who received a primary prevention ICD had a 25 percent reduction in total mortality (hazard ratio [HR] 0.75, 95% CI 0.67-0.83).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with comorbidities</strong> – Among 10 studies of primary prevention ICD use in patients with a variety of comorbidities (including renal disease, chronic obstructive pulmonary disease, and diabetes, among others), ICD implantation for primary prevention was associated with a 28 percent reduction in total mortality (HR 0.72, 95% CI 0.65-0.79), with similar findings in the "minimal overlap" meta-analysis, which included only five studies (HR 0.71, 95% CI 0.61-0.82).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with renal disease</strong> – Patients with chronic kidney disease requiring dialysis have increased mortality and reported high rates of SCD. Among five studies (two post-hoc analyses of randomized trial data and three observational studies) specifically looking at patients with varying degrees of chronic renal disease, primary prevention ICD use was associated with a 29 percent reduction in total mortality (HR 0.71, 95% CI 0.60-0.85). (See  <a class="medical medical_review" href="/z/d/html/1922.html" rel="external">"Evaluation of sudden cardiac arrest and sudden cardiac death in patients on dialysis"</a>.)</p><p></p><p>Following the systematic review for the 2017 AHA/ACC/HRS guidelines, additional studies have been published evaluating the role of primary prevention ICDs in older patients and those with severe kidney disease. While randomized trial data are absent, clinicians have shown a preference for using the totally subcutaneous ICD (S-ICD) in patients with severe kidney disease (in particular among patients who undergo regular hemodialysis) in order to reduce the risk of intravascular infection in this population [<a href="#rid79">79</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective multi-center cohort of 300 patients receiving a primary prevention ICD or CRT-D, which included 150 patients ≥80 years old (mean age 82 years, 76 percent with one or fewer comorbidities) and 150 patients &lt;80 years old (mean age 62 years, matched for sex and type of heart disease), similar numbers of patients received an appropriate shock (19.4 percent of older patients versus 21.6 percent of younger patients) with no significant difference in complication rates over mean follow-up of three years [<a href="#rid80">80</a>]. These data suggest that, compared with younger patients, primary prevention ICDs can be safely implanted in selected patients ≥80 years old with few or no comorbidities. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients on dialysis who did not meet standard indications for ICD therapy, the ICD2 trial was published suggesting no benefit from primary prevention ICDs [<a href="#rid81">81</a>]. In the ICD2 trial, 200 patients on dialysis who had an LVEF ≥35 percent without HF symptoms and no documented VT were randomized to ICD implantation with optimal medical therapy or to not receive an ICD. Following randomization of 188 patients, the trial was stopped prematurely due to futility, with no significant improvement among ICD recipients in five-year rates of SCD (9.7 versus 7.9 percent without ICD; HR 1.3, 95% CI 0.5-3.3) or overall survival (50.6 versus 54.4 percent without ICD; HR 1.0, 95% CI 0.7-1.5). While the results may be partially explained by the lower than expected observed rates of SCD in the study (annual rate of 2 percent versus expected rate of 5 to 6 percent), the data do not support extending primary prevention ICD use in dialysis beyond the standard indications. However, it should be noted that transvenous ICDs (often dual chamber systems) were utilized and significant complications occurred, including adverse events related to the ICD implantation procedure in 13 percent and ICD explantation (primarily due to bacteremia) in 7.5 percent. These results cannot necessarily be extrapolated to totally subcutaneous systems, which are frequently utilized in patients on dialysis as they appear to be associated with lower rates of bacteremia than transvenous systems. (See <a class="local">'Our approach for patients with ischemic cardiomyopathy'</a> above and <a class="local">'Our approach for patients with nonischemic dilated cardiomyopathy'</a> above and  <a class="medical medical_review" href="/z/d/html/97158.html" rel="external">"Subcutaneous implantable cardioverter defibrillators"</a>.) </p><p></p><p class="headingAnchor" id="H2262954416"><span class="h1">GAPS IN THE GUIDELINES</span></p><p class="headingAnchor" id="H957895585"><span class="h2">Possible indications not addressed by guidelines</span><span class="headingEndMark"> — </span>The HRS/ACC/AHA Expert Consensus Statement on the Use of ICD Therapy in Patients Who Are Not Included or Not Represented in Clinical Trials evaluated important clinical situations for which implantable cardioverter-defibrillator (ICD) therapy might be beneficial in selected populations that were not consistently included in randomized clinical trials and may not be included in guideline documents [<a href="#rid82">82</a>]. This document includes discussion related to the following topics:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of an ICD in patients with an abnormal troponin that is not due to a myocardial infarction (MI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of an ICD within 40 days after a MI, such as patients with preexisting left ventricular (LV) dysfunction or those requiring non-elective permanent pacing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of an ICD within the first 90 days after revascularization, such as patients with preexisting LV dysfunction or those requiring non-elective permanent pacing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of an ICD within the first nine months after initial diagnosis of nonischemic cardiomyopathy. </p><p></p><p>Recommendations were made based on available evidence as well as consensus opinion. Many clinical scenarios where gaps in evidence exist for ICD therapy are also discussed in the 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy (CRT) [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H957895591"><span class="h2">Patients undergoing generator replacement with improved LVEF and/or no prior ICD therapies</span><span class="headingEndMark"> — </span>An additional clinical scenario that is not fully covered in professional society guidelines and consensus documents is the management of patients who have received a primary prevention ICD who have improved or normalized LV function, have never received appropriate ICD therapy, and have either reached the point of elective replacement for their device or require reimplantation after system extraction (ie, due to infection) [<a href="#rid74">74,84-89</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Among a subset of 1273 patients from the SCD-HeFT trial (624 randomized to ICD, 649 randomized to placebo) who had repeat assessment of left ventricular ejection fraction (LVEF) at a mean of 13.5 months post-randomization, 371 patients (29 percent) showed improvement to LVEF &gt;35 percent (186 [29.8 percent] in ICD group versus 185 [28.5 percent] in placebo group) [<a href="#rid84">84</a>]. There was a similar reduction in all-cause mortality with the ICD in both the LVEF ≤35 percent group (adjusted hazard ratio [HR] 0.64, 95% CI 0.48-0.85) and the LVEF &gt;35 percent group (adjusted HR 0.62, 95% CI 0.29-1.30). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 752 patients from the MADIT-CRT study with mild HF symptoms, 7.3 percent had normalized LVEF to &gt;50 percent after cardiac resynchronization therapy (CRT; so-called "super-responders"); these "super-responders" had a low rate of ventricular arrhythmias, with only 3 of 55 super-responders (5 percent) having treated VT (none requiring an ICD shock) at a mean follow-up of 2.2 years [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 231 patients with an ICD placed for primary prevention, 26 percent had shown enough improvement in LVEF to no longer meet implant criteria at the time of elective generator replacement [<a href="#rid86">86</a>]. Patients in whom LVEF improved had a lower rate of appropriate therapy after generator replacement (2.8 percent per year) than those whose LVEF remained ≤35 percent (10.7 percent per year). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among a prospective cohort of 538 patients from the PROSE-ICD study who received a primary prevention ICD and had subsequent reassessment of LVEF, 40 percent of patients had &gt;5 percent improvement in LVEF (over 4.9 years of follow-up), of whom 25 percent had improvement in LVEF to &gt;35 percent [<a href="#rid87">87</a>]. Risk of an appropriate shock was significantly lower (but not completely eliminated) in patients with improved LVEF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among a cohort of 1421 patients with an ICD (49 percent primary prevention, 51 percent secondary prevention) scheduled to undergo generator replacement an average of 3.5 years following initial implantation, 471 patients (33 percent) had received an appropriate shock prior to replacement [<a href="#rid90">90</a>]. Following generator replacement, 435 patients (31 percent) received an appropriate ICD therapy during mean follow-up of 2.7 years. Patients with prior appropriate ICD therapy were significantly more likely to receive additional therapy following generator replacement (HR 3.0, 95% CI 2.4-3.7). </p><p></p><p>With limited observational data and no randomized trial data to guide decision making for patients with normalized LVEF, clinicians need to weigh a number of factors when planning generator replacement or system reimplantation in such patients, including original indication, possibility of relapse in LV dysfunction, overall prognosis, comorbidities, and patient preference. The 2013 ACC/HRS/AHA Appropriate Use Criteria suggest that replacement of CRT-D with CRT-P devices "may be appropriate" in selected patients who underwent initial ICD implantation for primary prevention indications if substantial improvement in LV function is noted (LVEF now &gt;35 percent, and particularly if ≥50 percent), if no clinically relevant ventricular arrhythmias have occurred [<a href="#rid83">83</a>]. However, due to the paucity of prospective data on this topic, it is also considered appropriate to replace a CRT-D device with a new CRT-D device in situations where LV function has improved [<a href="#rid83">83</a>]. </p><p class="headingAnchor" id="H539451771"><span class="h1">PROGNOSTIC SIGNIFICANCE OF ICD SHOCKS AND DEVICE PROGRAMMING</span><span class="headingEndMark"> — </span>Among patients with HF receiving implantable cardioverter-defibrillators (ICDs) for primary prevention in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), an appropriate shock, as compared with no appropriate shock, was associated with substantially increased all-cause mortality (hazard ratio [HR] 5.7, 95% CI 4.0-8.1) [<a href="#rid91">91</a>]. An inappropriate shock, as compared with no inappropriate shock, was also associated with a significant increase in mortality (HR 2.0, 95% CI 1.3-3.1). The most common cause of death among patients who received any ICD shock was progressive HF. Other studies have also shown that appropriate or inappropriate shocks are associated with increased mortality [<a href="#rid92">92,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/3501.html" rel="external">"Prognosis of heart failure"</a>.)</p><p>Several trials have underscored the importance of reducing both appropriate and inappropriate shocks through optimizing ICD programming. The Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) study found improved survival in ICD recipients who were randomly assigned to ICD programming with a high rate cutoff and/or long detection times, both of which were associated with fewer ICD shocks compared with conventional programming [<a href="#rid94">94</a>]. The Avoiding Defibrillator Therapies For Non-sustained Arrhythmias In ICD Patients (ADVANCE) III trial found a similar benefit for extended detection time in reducing both appropriate and inappropriate ICD shocks [<a href="#rid95">95</a>]. The 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing outlines the importance of proper ICD programming in reducing unnecessary therapy [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/z/d/html/113776.html" rel="external">"Implantable cardioverter-defibrillators: Optimal programming"</a>.)</p><p class="headingAnchor" id="H28315617"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a>.)</p><p class="headingAnchor" id="H362964755"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15665.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3442.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H31279510"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification strategies </strong>– While implantable cardioverter-defibrillators (ICDs) are highly efficacious in the treatment of ventricular tachyarrhythmias and prevention of sudden cardiac death (SCD), they are costly, require ongoing follow-up, and have acute procedural and long-term risks (eg, infection, device and lead malfunction, etc). Because only a subset of patients with cardiomyopathy develop sustained ventricular tachyarrhythmias or SCD, risk stratification of patients prior to considering ICD therapy is important. (See <a class="local">'Risk stratification strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendations for selecting the optimal patients for ICD therapy </strong>– These are based largely upon the entry criteria in the major trials. Prior to recommending ICD therapy for the primary prevention of SCD, there should be a reasonable expectation of survival with a good functional status for at least one year regardless of the indication for ICD therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who meet criteria for insertion of an ICD for the primary prevention of SCD, in the absence of a contraindication, we recommend optimizing guideline-directed medical therapy with a beta blocker and either an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker <strong>prior</strong> to ICD implantation (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Guideline-directed medical therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with cardiomyopathy due to ischemic heart disease, left ventricular ejection fraction (LVEF) ≤35 percent, and associated heart failure (HF) with New York Heart Association (NYHA) functional class II or III status, we recommend ICD therapy for primary prevention of SCD (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Patients should be evaluated at least 40 days post-myocardial infarction (MI) and more than three months following revascularization. (See <a class="local">'Ischemic cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with cardiomyopathy due to ischemic heart disease, LVEF ≤30 percent, and NYHA functional class I status, we recommend ICD therapy for primary prevention of SCD (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Patients should be evaluated at least 40 days post-MI and more than three months following revascularization. (See <a class="local">'Ischemic cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with nonischemic dilated cardiomyopathy, LVEF ≤35 percent, and associated HF with NYHA functional class II or III symptoms, we suggest ICD therapy for primary prevention of SCD rather than optimal medical therapy alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). ICDs are very effective at reducing total mortality and mortality from SCD, although the benefits of an ICD on total mortality may be diminished in the setting of guideline-directed optimal medical therapy and cardiac resynchronization therapy (CRT). All patients receiving an ICD for primary prevention of SCD should be treated with at least three months of guideline-directed medical therapy prior to ICD implantation. It is important to note that some patients continue to show improvement of left ventricular function after a longer duration of medical therapy prior to ICD implantation. (See <a class="local">'Nonischemic dilated cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an LVEF ≤35 percent, HF with NYHA functional class III or IV status, and a QRS duration ≥120 milliseconds, we recommend implantation of a combined CRT-D device (biventricular pacing combined with an ICD) rather than an ICD alone (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Strongest consideration for the CRT component should be given for those patients with left bundle branch block (LBBB) QRS morphology, those with QRS duration ≥150 milliseconds, and those dependent upon ventricular pacing due to atrioventricular block. (See <a class="local">'Trials of primary prevention ICDs in nonischemic dilated cardiomyopathy'</a> above and  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The role of ICD therapy for primary prevention of SCD in patients with HF and NYHA class IV status who have a narrow QRS complex has not been well-studied, as NYHA class IV patients have generally been excluded from randomized primary prevention ICD trials due to high expected mortality rate. For ambulatory patients with NYHA class IV HF, an LVEF ≤35 percent, and a narrow QRS complex (ie, no dyssynchrony) who are awaiting cardiac transplantation outside the hospital, it is reasonable to consider ICD implantation as a bridge to transplantation. (See <a class="local">'Class IV heart failure'</a> above.) </p><p></p><p class="headingAnchor" id="H26341934"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Leonard Ganz, MD, FHRS, FACC, and Scott Manaker, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Hellkamp AS, Fonarow GC, et al. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. JAMA 2014; 311:2209.</a></li><li><a class="nounderline abstract_t">Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol 2012; 60:1647.</a></li><li><a class="nounderline abstract_t">Hong C, Alluri K, Shariff N, et al. Usefulness of the CHA2DS2-VASc Score to Predict Mortality in Defibrillator Recipients. Am J Cardiol 2017; 120:83.</a></li><li><a class="nounderline abstract_t">Zeitler EP, Hellkamp AS, Fonarow GC, et al. Primary prevention implantable cardioverter-defibrillators and survival in older women. JACC Heart Fail 2015; 3:159.</a></li><li><a class="nounderline abstract_t">Zhang Y, Guallar E, Blasco-Colmenares E, et al. Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients. Heart Rhythm 2015; 12:360.</a></li><li><a class="nounderline abstract_t">Nevzorov R, Goldenberg I, Konstantino Y, et al. Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry. J Cardiovasc Electrophysiol 2018; 29:1540.</a></li><li><a class="nounderline abstract_t">Bilchick KC, Wang Y, Cheng A, et al. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. J Am Coll Cardiol 2017; 69:2606.</a></li><li><a class="nounderline abstract_t">Kristensen SL, Levy WC, Shadman R, et al. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial. JACC Heart Fail 2019; 7:717.</a></li><li><a class="nounderline abstract_t">Levy WC, Li Y, Reed SD, et al. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? JACC Clin Electrophysiol 2017; 3:291.</a></li><li><a class="nounderline abstract_t">Levy WC, Hellkamp AS, Mark DB, et al. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. JACC Clin Electrophysiol 2018; 4:1089.</a></li><li><a class="nounderline abstract_t">Shadman R, Poole JE, Dardas TF, et al. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. Heart Rhythm 2015; 12:2069.</a></li><li><a class="nounderline abstract_t">Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996; 27:1119.</a></li><li><a class="nounderline abstract_t">Touboul P, Andre-Fouët X, Leizorovicz A, et al. Risk stratification after myocardial infarction. A reappraisal in the era of thrombolysis. The Groupe d'Etude du Pronostic de l'Infarctus du Myocarde (GREPI). Eur Heart J 1997; 18:99.</a></li><li><a class="nounderline abstract_t">Schmitt C, Barthel P, Ndrepepa G, et al. Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. J Am Coll Cardiol 2001; 37:1901.</a></li><li><a class="nounderline abstract_t">Di Marco A, Anguera I, Schmitt M, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail 2016.</a></li><li><a class="nounderline abstract_t">Gutman SJ, Costello BT, Papapostolou S, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J 2019; 40:542.</a></li><li class="breakAll">https://www.centerwatch.com/clinical-trials/listings/217964/clinical-electrocardiographic-and-cardiac-magnetic-resonance-imaging-risk-factors-associated-with-ventricular-tachyarrhythmias-in-nonischemic-cardiomyopathy-marven-study/ (Accessed on May 01, 2019).</li><li><a class="nounderline abstract_t">Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101:1800.</a></li><li><a class="nounderline abstract_t">Kühlkamp V, InSync 7272 ICD World Wide Investigators. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. J Am Coll Cardiol 2002; 39:790.</a></li><li><a class="nounderline abstract_t">Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.</a></li><li><a class="nounderline abstract_t">Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.</a></li><li><a class="nounderline abstract_t">Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 2002; 106:2466.</a></li><li><a class="nounderline abstract_t">Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337:1569.</a></li><li><a class="nounderline abstract_t">Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877.</a></li><li><a class="nounderline abstract_t">Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.</a></li><li><a class="nounderline abstract_t">Poole JE, Olshansky B, Mark DB, et al. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. J Am Coll Cardiol 2020; 76:405.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481.</a></li><li><a class="nounderline abstract_t">Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361:1427.</a></li><li><a class="nounderline abstract_t">Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151.</a></li><li><a class="nounderline abstract_t">Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539.</a></li><li><a class="nounderline abstract_t">Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140.</a></li><li><a class="nounderline abstract_t">Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol 2012; 23:163.</a></li><li><a class="nounderline abstract_t">Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011; 171:1454.</a></li><li><a class="nounderline abstract_t">Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60:1297.</a></li><li><a class="nounderline abstract_t">Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375:1221.</a></li><li><a class="nounderline abstract_t">Golwala H, Bajaj NS, Arora G, Arora P. Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis. Circulation 2017; 135:201.</a></li><li><a class="nounderline abstract_t">Shun-Shin MJ, Zheng SL, Cole GD, et al. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J 2017; 38:1738.</a></li><li><a class="nounderline abstract_t">Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Electrophysiol 2017; 28:659.</a></li><li><a class="nounderline abstract_t">Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167:103.</a></li><li><a class="nounderline abstract_t">Luni FK, Singh H, Khan AR, et al. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Electrophysiol 2017; 28:538.</a></li><li><a class="nounderline abstract_t">Anantha Narayanan M, Vakil K, Reddy YN, et al. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol 2017; 3:962.</a></li><li><a class="nounderline abstract_t">Beggs SAS, Jhund PS, Jackson CE, et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart 2018; 104:144.</a></li><li><a class="nounderline abstract_t">Alba AC, Foroutan F, Duero Posada J, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart 2018; 104:230.</a></li><li><a class="nounderline abstract_t">El Moheb M, Nicolas J, Khamis AM, et al. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. Cochrane Database Syst Rev 2018; 12:CD012738.</a></li><li><a class="nounderline abstract_t">Nuttall SL, Toescu V, Kendall MJ. beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 2000; 320:581.</a></li><li><a class="nounderline abstract_t">Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 7:1.</a></li><li><a class="nounderline abstract_t">Brodine WN, Tung RT, Lee JK, et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol 2005; 96:691.</a></li><li><a class="nounderline abstract_t">Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893.</a></li><li><a class="nounderline abstract_t">McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993.</a></li><li><a class="nounderline abstract_t">Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42:81.</a></li><li><a class="nounderline abstract_t">Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005; 95:490.</a></li><li><a class="nounderline abstract_t">Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007; 153:573.</a></li><li><a class="nounderline abstract_t">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.</a></li><li><a class="nounderline abstract_t">Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 2021; 42:3727.</a></li><li><a class="nounderline abstract_t">Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm 2021; 18:1098.</a></li><li><a class="nounderline abstract_t">Miller AL, Wang Y, Curtis J, et al. Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry. Arch Intern Med 2012; 172:64.</a></li><li><a class="nounderline abstract_t">Duncker D, König T, Hohmann S, et al. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9.</a></li><li><a class="nounderline abstract_t">Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857.</a></li><li><a class="nounderline abstract_t">Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109:990.</a></li><li><a class="nounderline abstract_t">Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004; 43:39.</a></li><li><a class="nounderline abstract_t">Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118:433.</a></li><li><a class="nounderline abstract_t">Hallstrom A, Pratt CM, Greene HL, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995; 25:1250.</a></li><li><a class="nounderline abstract_t">Slater W, Lampert S, Podrid PJ, Lown B. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988; 61:349.</a></li><li><a class="nounderline abstract_t">Gottlieb SS, Kukin ML, Medina N, et al. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 1990; 81:860.</a></li><li><a class="nounderline abstract_t">Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14:1326.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1.</a></li><li><a class="nounderline abstract_t">Saba S, Atiga WL, Barrington W, et al. Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. J Heart Lung Transplant 2003; 22:411.</a></li><li><a class="nounderline abstract_t">Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol 2010; 56:194.</a></li><li><a class="nounderline abstract_t">Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, et al. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation. Transplant Proc 2013; 45:3659.</a></li><li><a class="nounderline abstract_t">Barra S, Providência R, Paiva L, et al. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace 2015; 17:174.</a></li><li><a class="nounderline abstract_t">Pun PH, Al-Khatib SM, Han JY, et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014; 64:32.</a></li><li><a class="nounderline abstract_t">Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8:179.</a></li><li><a class="nounderline abstract_t">Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014; 2:623.</a></li><li><a class="nounderline abstract_t">Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:1653.</a></li><li><a class="nounderline abstract_t">Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. JAMA Cardiol 2016; 1:900.</a></li><li><a class="nounderline abstract_t">Zakine C, Garcia R, Narayanan K, et al. Prophylactic implantable cardioverter-defibrillator in the very elderly. Europace 2019; 21:1063.</a></li><li><a class="nounderline abstract_t">Jukema JW, Timal RJ, Rotmans JI, et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation 2019; 139:2628.</a></li><li><a class="nounderline abstract_t">Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation 2014; 130:94.</a></li><li><a class="nounderline abstract_t">Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013; 61:1318.</a></li><li><a class="nounderline abstract_t">Adabag S, Patton KK, Buxton AE, et al. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol 2017; 2:767.</a></li><li><a class="nounderline abstract_t">Ruwald MH, Solomon SD, Foster E, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 2014; 130:2278.</a></li><li><a class="nounderline abstract_t">Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol 2014; 63:2388.</a></li><li><a class="nounderline abstract_t">Zhang Y, Guallar E, Blasco-Colmenares E, et al. Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients. J Am Coll Cardiol 2015; 66:524.</a></li><li><a class="nounderline abstract_t">Madeira M, António N, Milner J, et al. Who still remains at risk of arrhythmic death at time of implantable cardioverter-defibrillator generator replacement? Pacing Clin Electrophysiol 2017; 40:1129.</a></li><li><a class="nounderline abstract_t">Weng W, Sapp J, Doucette S, et al. Benefit of Implantable Cardioverter-Defibrillator Generator Replacement in a Primary Prevention Population-Based Cohort. JACC Clin Electrophysiol 2017; 3:1180.</a></li><li><a class="nounderline abstract_t">Witt CM, Waks JW, Mehta RA, et al. Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement. Circ Arrhythm Electrophysiol 2018; 11:e006155.</a></li><li><a class="nounderline abstract_t">Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009.</a></li><li><a class="nounderline abstract_t">Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51:1357.</a></li><li><a class="nounderline abstract_t">Dichtl W, Wolber T, Paoli U, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol 2011; 34:433.</a></li><li><a class="nounderline abstract_t">Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275.</a></li><li><a class="nounderline abstract_t">Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013; 309:1903.</a></li><li><a class="nounderline abstract_t">Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm 2016; 13:e50.</a></li></ol></div><div id="topicVersionRevision">Topic 91077 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10376614" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24893088" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021331" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28479166" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Usefulness of the CHA2DS2-VASc Score to Predict Mortality in Defibrillator Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25543969" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Primary prevention implantable cardioverter-defibrillators and survival in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25446153" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168227" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28545633" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302052" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28553663" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139491" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142301" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609330" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049521" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk stratification after myocardial infarction. A reappraisal in the era of thrombolysis. The Groupe d'Etude du Pronostic de l'Infarctus du Myocarde (GREPI)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401129" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28017348" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30107489" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30107489" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26269413" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Individual patient data network meta-analysis of mortality effects of implantable cardiac devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869843" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960472" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601507" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417544" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371853" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907286" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659722" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703511" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15590950" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19812399" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Defibrillator implantation early after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15152060" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753115" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effect of cardiac resynchronization on morbidity and mortality in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15152059" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21815961" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670335" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975230" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27571011" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27993908" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329280" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28316104" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632280" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28370885" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759721" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28986406" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780582" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30537022" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688573" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510232" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125497" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080457" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14610160" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25176015" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Angiotensin-neprilysin inhibition versus enalapril in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849664" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695135" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383296" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668699" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448003" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33757845" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082711" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28096098" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023943" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10486417" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967728" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715180" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2476016" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722117" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124591" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2106401" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2509529" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Congestive heart failure induced by six of the newer antiarrhythmic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24685669" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681418" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620738" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314988" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25480942" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518128" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25669833" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25306452" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097297" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27603935" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30891608" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prophylactic implantable cardioverter-defibrillator in the very elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882234" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815500" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453819" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28724134" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301831" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24727249" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26227190" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28842918" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Who still remains at risk of arrhythmic death at time of implantable cardioverter-defibrillator generator replacement?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759503" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Benefit of Implantable Cardioverter-Defibrillator Generator Replacement in a Primary Prevention Population-Based Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354311" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768944" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prognostic importance of defibrillator shocks in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387436" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21678454" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23131066" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Reduction in inappropriate therapy and mortality through ICD programming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652522" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26607062" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
